Sankala Group’s Immunovant IMVT Stock Holding History

Sankala Group’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.53K	Hold	150	–	–	﹤0.01%	444
2026 Q1	$3.71K	Hold	150	–	–	﹤0.01%	453
2025 Q4	$4.16K	Buy	+150	New	+$3.35K	﹤0.01%	460

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sankala Group's IMVT Position: Q2 2026 in Review

Sankala Group held its Immunovant (IMVT) position steady in Q2 2026 at 150 shares worth $6.53K. The position accounts for ﹤0.01% of the portfolio, ranked #444.

Sankala Group first reported a position in IMVT in Q4 2025 and has held it in 3 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

Sankala Group held 150 shares of Immunovant worth $6.53K as of Q2 2026.
Sankala Group left its Immunovant share count unchanged in Q2 2026.
Immunovant made up ﹤0.01% of Sankala Group's portfolio in Q2 2026, its #444 holding.
Sankala Group first reported a position in Immunovant in Q4 2025 and has held it in 3 quarters since.
226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Sankala Group's 13F filing for Q2 2026, filed 18 Aug 2026.